These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11853960)

  • 1. Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.
    Mooney MH; Abdel-Wahab YH; McKillop AM; O'Harte FP; Flatt PR
    Biochim Biophys Acta; 2002 Jan; 1569(1-3):75-80. PubMed ID: 11853960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells.
    O'Harte FP; Abdel-Wahab YH; Conlon JM; Flatt PR
    Diabetologia; 1998 Oct; 41(10):1187-93. PubMed ID: 9794106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.
    O'Harte FP; Mooney MH; Lawlor A; Flatt PR
    Biochim Biophys Acta; 2000 Mar; 1474(1):13-22. PubMed ID: 10699485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle.
    O'Harte FP; Gray AM; Abdel-Wahab YH; Flatt PR
    Peptides; 1997; 18(9):1327-33. PubMed ID: 9392833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ; McIntosh CH; Pederson RA
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice.
    Mooney MH; Abdel-Wahab YH; Morgan LM; O'Harte FP; Flatt PR
    Endocrine; 2001 Dec; 16(3):167-71. PubMed ID: 11954659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.
    Gros L; Thorens B; Bataille D; Kervran A
    Endocrinology; 1993 Aug; 133(2):631-8. PubMed ID: 8102095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line.
    Crespel A; De Boisvilliers F; Gros L; Kervran A
    Endocrinology; 1996 Sep; 137(9):3674-80. PubMed ID: 8756532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system.
    Takhar S; Gyomorey S; Su RC; Mathi SK; Li X; Wheeler MB
    Endocrinology; 1996 May; 137(5):2175-8. PubMed ID: 8612565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 content of intestinal tract in adult rats injected with streptozotocin either during neonatal period or 7 d before sacrifice.
    Cancelas J; Sancho V; Villanueva-Peñacarrillo ML; Courtois P; Scott FW; Valverde I; Malaisse WJ
    Endocrine; 2002 Dec; 19(3):279-86. PubMed ID: 12624427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms involved in glucagon-like peptide-1 (7-36) amide action on the rat hypothalamo-neurohypophysial system.
    Bojanowska E; Stempniak B
    Neuroendocrinology; 2003 Feb; 77(2):119-24. PubMed ID: 12624533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
    Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
    Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.
    Nakabayashi H; Nishizawa M; Nakagawa A; Takeda R; Niijima A
    Am J Physiol; 1996 Nov; 271(5 Pt 1):E808-13. PubMed ID: 8944665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
    Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
    J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.
    Marie JC; Boissard C; Skoglund G; Rosselin G; Breant B
    Endocrinology; 1996 Oct; 137(10):4108-14. PubMed ID: 8828464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
    Roberge JN; Brubaker PL
    Endocrinology; 1993 Jul; 133(1):233-40. PubMed ID: 8319572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.